1-3 of 3
Keywords: hepatocellular carcinoma (HCC)
Follow your search
Access your saved searches in your account

Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Clin Sci (Lond) (2015) 128 (11): 761–774.
Published: 17 March 2015
... promoter. In the present study, we investigate Smad7 overexpression as a pathophysiological mechanism for cytostatic TGF-β inhibition in liver damage and hepatocellular carcinoma (HCC). Transgenic hepatocyte-specific Smad7 overexpression in damaged liver of fumarylacetoacetate hydrolase (FAH)-deficient...
Includes: Supplementary data
Clin Sci (Lond) (2015) 128 (1): 29–37.
Published: 27 August 2014
...Jan Peveling-Oberhag; Claudia Döring; Sylvia Hartmann; Natalie Filmann; Angelika Mertens; Albrecht Piiper; Eva Herrmann; Martin-Leo Hansmann; Stefan Zeuzem; Jörg Trojan; Martin-Walter Welker Sorafenib is the standard treatment for patients with advanced hepatocellular carcinoma (HCC). However, the...
Includes: Supplementary data
Clin Sci (Lond) (2008) 114 (7): 467–477.
Published: 29 February 2008
... hepatocellular carcinoma (HCC) inflammation liver vascular endothelial growth factor (VEGF) Blood vessels arise from endothelial precursors, which share a common origin with haemopoietic progenitors. These progenitors assemble into an early vascular labyrinth of small capillaries. At this stage, these...